
Opinion|Videos|November 19, 2024
Safety Profiles of Neurokinin-Targeted Therapies for VMS
Key Takeaways
- Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
- The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- (PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
- (FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Guideline-Directed Medical Therapies in Heart Failure
2
Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD
3
Collaboration in Heart Failure Treatment
4
Coordinating Medications for Women With Arrhythmia: Lindsey Valenzuela, PharmD
5